Lupin Q3 FY25 profit up 40% at Rs. 855 Cr

Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore

Cupid receives Rs. 13.90 cr order for female condoms from Brazil, South Africa and Angola

The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL

FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL

Approval is based on positive data from the Phase 3 ECHELON-3 trial

Peter Bains to replace Jonathan Hunt as CEO of Syngene

Peter Bains has over three decades of experience in the biotech and pharmaceutical industry

Lupin receives approval from USFDA for Ipratropium Bromide Nasal Solution

Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis

NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension

TFOS is indicated for the treatment of pulmonary arterial hypertension

Jagsonpal Pharmaceuticals appoints Sachin Jain as CFO

He has over 23 years of experience across sectors

Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru

Zydus Lifesciences posts Q3 FY25 net profit higher at Rs 1,024 Cr

During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK